BET Inhibitors Plus Sunitinib Induce Early Signs of Clinical Activity in Melanoma Cells
Source: OncLive, March 2023
Sunitinib (Sutent) demonstrated synergistic activity with the BET inhibitors JQ1 and NHWD-870 in melanoma cell lines, according to preclinical findings from a study that were published in Experimental & Molecular Medicine.
This study showed that BET inhibitors inhibit the BRD4/GDF15 and BRD4/IL6/STAT3/GDF15 pathways, thus sensitizing melanoma cell lines to sunitinib.
“These findings suggest that BET inhibitor–mediated GDF15 inhibition plays a critical role in enhancing sunitinib sensitivity in melanoma, indicating that BET inhibitors synergize with sunitinib in melanoma,” lead study author Furong Zeng, of the Xiangya Clinical Research Center for Cancer Immunotherapy in Changsha, Hunan, China, and colleagues, wrote in a paper of the data.